Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign to Raise Awareness and Educate Consumers on Diabeti...
May 22 2019 - 8:00AM
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the
commercialization and development of prescription ophthalmology
treatments for the management of retinal diseases, announces the
launch of a direct-to-patient (DTP) marketing campaign intended to
raise awareness and educate patients diagnosed with diabetic
macular edema (DME) and their caregivers about the therapeutic and
dosing benefits of ILUVIEN. The campaign will be supported by the
website www.iluvienmoments.com.
The Company will utilize digital, radio, and in-office marketing
programs highlighting the benefits of ILUVIEN in addressing
challenges faced by patients with DME. The initial DTP campaign
will pilot in four U.S. cities, with potential for future expansion
as determined by the Company. Interested parties can access
the radio spot here.
With its patented and proprietary CONTINUOUS MICRODOSING™
technology, ILUVIEN is a sustained-release intravitreal implant
that is administered directly into the eye to control the
recurrence of DME. In clinical trials, ILUVIEN has demonstrated the
ability to reduce edema in the retina for up to 36 months with one
intra-ocular injection, thereby enabling patients to maintain
vision longer with fewer injections.
“We believe ILUVIEN is extremely attractive to patients
suffering from DME, according to our research,” said Rick Eiswirth,
Alimera’s President and Chief Executive Officer. “However, patient
awareness of ILUVIEN itself is relatively low. Therefore, we are
launching our initial DTP campaign in select cities, to educate and
empower DME patients and their caregivers to ask their doctor if
ILUVIEN treatment is right for them.”
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic
retinopathy, is a disease affecting the macula, the part of the
retina responsible for central vision. When the blood vessel
leakage associated with diabetic retinopathy results in swelling of
the macula, the condition is called DME. The onset of DME is
painless and may go unreported by the patient until it manifests
with the blurring of central vision or acute vision loss. The
severity of this blurring may range from mild to profound loss of
vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy
found that over a 10-year period, approximately 19% of people with
diabetes included in the study were diagnosed with DME. All people
with type 1 or type 2 diabetes are at risk of developing DME.
About ILUVIEN
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is
a sustained release intravitreal implant, injected into the back of
the eye. With its CONTINUOUS MICRODOSING™ technology, ILUVIEN is
designed to release submicrogram levels of fluocinolone acetonide,
a corticosteroid, for 36 months, to control the recurrence of
disease, enabling patients to maintain vision longer with fewer
injections. ILUVIEN is approved in the U.S., Canada, Kuwait,
Lebanon and the U.A.E to treat diabetic macular edema (DME) in
patients who have been previously treated with a course of
corticosteroids and did not have a clinically significant rise in
intraocular pressure. In 17 European countries, ILUVIEN is
indicated for the treatment of vision impairment associated with
chronic DME considered insufficiently responsive to available
therapies. In March 2019, ILUVIEN received approval in the 17
countries under the Mutual Recognition Procedure for prevention of
relapse in recurrent non-infectious uveitis affecting the posterior
segment of the eye. The 17 EU countries include the UK, Germany,
France, Italy, Spain, Portugal, Ireland, Austria, Belgium, Denmark,
Norway, Finland, Sweden, Poland, Czech Republic, the Netherlands,
and Luxembourg. The regulatory process is now in the national
phase in which the U.K. and each additional European member state
are expected to finalize the label for the new indication to meet
each country’s local requirements. Timeline to this goal varies by
each country.
See www.ILUVIEN.com for important safety information.
About Alimera Sciences, Inc.
www.alimerasciences.com
Alimera, founded in June 2003, is a pharmaceutical company that
specializes in the commercialization and development of
prescription ophthalmic pharmaceuticals. Alimera is presently
focused on diseases affecting the back of the eye, or retina,
because these diseases are not well treated with current therapies
and will affect millions of people in our aging populations. For
more information, please visit www.alimerasciences.com.
Forward Looking Statements
This press release contains “forward-looking statements,” within
the meaning of the Private Securities Litigation Reform Act of
1995, regarding, among other things, Alimera’s belief that the DTP
pilot will be effective with patients and that increased awareness
will have the intended effect. Such forward-looking statements are
based on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
either of them, and could cause actual results to differ materially
from those projected in its forward-looking statements. Meaningful
factors that could cause actual results to differ include, but are
not limited to, other factors discussed in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” sections of Alimera’s Annual Report on Form
10-K for the year ended December 31, 2018, which is on file with
the Securities and Exchange Commission and available on its website
at http://www.sec.gov.
For press inquiries: |
|
|
For investor inquiries: |
Jules Abraham |
|
|
Scott Gordon |
for Alimera Sciences |
|
|
for Alimera Sciences |
917-885-7378 |
|
|
scottg@coreir.com |
julesa@coreir.com |
|
|
|
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2023 to Apr 2024